Imaging mutant huntingtin in the brain

[11C]CHDI-39 180R allowed for non-invasive monitoring of mHTT pathology in the brain and could track region and time-dependent suppression of mHTT in response to therapeutic interventions targeting mHTT.

Read more:

Development of a ligand for in vivo imaging of mutant huntingtin in Huntington’s disease

Bertoglio, D., Bard, J., Hessmann, M., Liu, L., Gärtner, A., De Lombaerde, S., Huscher, B., Zajicek, F., Miranda, A., Peters, F., Herrmann, F., Schaertl, S., Vasilkovska, T., Brown, C. J., Johnson, P. D., Prime, M. E., Mills, M. R., Van der Linden, A., Mrzljak, L., Khetarpal, V., … Munoz-Sanjuan, I. (2022). Science translational medicine, 14(630), eabm3682. https://doi.org/10.1126/scitranslmed.abm3682